Evaluation des Krankheitsverlaufs von Patienten mit Diabetes mellitus Typ 2 der Diabetesambulanz der UMG anhand laborchemischer und klinischer Parameter – eine retrospektive Analyse des Zeitraums 2014 bis 2021
Abstract
The aim of this doctoral thesis was to investigate the disease progression and treatment courses of patients with type 2 diabetes at the diabetes outpatient department of University Medical Center Göttingen between the periods 2014–2015 (t0) and 2019–03/2021 (t1). Since the mid-2010s, several major studies have been published showing the benefits of SGLT2 inhibitors (e.g. EMPA-REG OUTCOME for empagliflozin) and GLP-1 receptor agonists (GLP-1 RA) (e.g. LEADER for liraglutide) concerning key cardiovascular outcomes for patients with type 2 diabetes and elevated cardiovascular risk. Therefore, these drug classes gained increasing importance in guideline recommendations for type 2 diabetes. This thesis aimed to assess how the treatment regimens of patients in this outpatient department evolved in light of these new therapeutic recommendations over the aforementioned periods. In the second step, changes in key clinical and laboratory parameters (insulin requirements, BMI, HbA1c, renal values) were evaluated. A secondary aspect involved investigating cardiovascular risk and lipid-lowering therapy in the context of LDL cholesterol target levels. A total of 132 patients were included. In addition to a longitudinal analysis of the entire cohort, a subgroup analysis was also conducted. The subgroup classification was based on whether a patient received an SGLT2 inhibitor, a GLP-1 RA, a combination of both drug classes, or none of these medications over the course of treatment.…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 132 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.